个人简介
教育经历
1989年毕业于南京大学生物化学系,获理学学士学位
1998年毕业于华中科技大学同济医学院(原同济医科大学),获生物化学与分子生物学专业硕士学位
2007年毕业于中山大学,获肿瘤学专业硕士学位
留学经历
2008年-2009年在美国印第安纳大学医学院进修(博士后),主要从事肿瘤放化疗耐受机制及DNA损伤修复蛋白翻译调控的研究。
研究领域
1. 消化系统及泌尿系统肿瘤基因组学及其发生发展及转移的分子机制研究
2. 肿瘤靶向性生物治疗基础研究以及药物的研发
3. 肿瘤放、化疗敏感/耐受相关基因及增敏剂的研究
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Wang X#, Cao Z#, Yue X#, Liu T, Wen G, Jiang D, Wu W, Le L, Wang Y, Wang C, Wang Z, Jin M, Zhu M, He S, Zhang X, Bu X, Liu R-y*, Peng Z*, Chen Y*. Stabilization of DEPTOR 1 sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation. Mol Ther Oncolytics. 2022 Aug 5;26:330-346. doi: 10.1016/j.omto.2022.08.002. (IF: 6.311)
2. Peng QH#, Wang CH#, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY*. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 2021 Feb; 9(2): e001638. doi: 10.1136/jitc-2020-001638. (IF: 12.469)
3. Zhou QH#, Han H#,*, Lu JB, Liu TY, Huang KB, Deng CZ, Li ZS, Chen JP, Yao K, Qin ZK, Liu ZW, Li YH, Guo SJ, Ye YL, Zhou FJ, Liu RY*. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients. Cancer Commun (Lond). 2020 Jan; 40(1): 3-15. doi: 10.1002/cac2.12001. (IF: 15.283)
4. Wang XC#, Yue X#,*, Zhang RX#, Liu TY, Pan ZZ, Yang MJ, Lu ZH, Wang ZY, Peng JH, Le LY, Wang GY, Peng QH, Meng Y, Huang W*, Liu RY*. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair. Clin Cancer Res. 2019 Jul 15;25(14):4567-4579. doi: 10.1158/1078-0432.CCR-18-3735 (IF: 13.801)
5. Liu GC#, Liu RY#, Yan JP#, An X#, Jiang W#, Ling YH, Chen JW, Bei JX, Zuo XY, Cai MY, Liu ZX, Zuo ZX, Liu JH*, Pan ZZ*, Ding PR*. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. JNCI-J NATL CANCER I. 2018 Sep 1; 110(9):975-984. doi: 10.1093/jnci/djy004 (IF: 11.816)